Trial
NCT02926638
Lung-MAP: Rilotumumab and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
SWOG Cancer Research Network
Collaborators
National Cancer Institute (NCI)
Condition
MET Positive
Intervention
Erlotinib Hydrochloride
Why stopped
Drug company decided to terminate all sponsored clinical studies involving rilotumumab.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-03-19